The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2015

Filed:

Jan. 30, 2013
Applicants:

Perry Peters, San Diego, CA (US);

David Furlano, San Diego, CA (US);

Daun Bahr, San Diego, CA (US);

Daniel Van Kammen, San Diego, CA (US);

Inventors:

Perry Peters, San Diego, CA (US);

David Furlano, San Diego, CA (US);

Daun Bahr, San Diego, CA (US);

Daniel Van Kammen, San Diego, CA (US);

Mark Brann, Rye, NH (US);

Assignee:

ACADIA Pharmaceuticals Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/4468 (2006.01); A61K 31/45 (2006.01); A61K 31/00 (2006.01); A61K 31/4515 (2006.01); A61K 31/5513 (2006.01); A61K 31/554 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/00 (2013.01); A61K 31/4468 (2013.01); A61K 31/4515 (2013.01); A61K 31/5513 (2013.01); A61K 31/554 (2013.01);
Abstract

Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.


Find Patent Forward Citations

Loading…